Literature DB >> 33833055

Cardiolipin aids in lipopolysaccharide transport to the gram-negative outer membrane.

Martin V Douglass1, François Cléon1, M Stephen Trent2,3.   

Abstract

In Escherichia coli, cardiolipin (CL) is the least abundant of the three major glycerophospholipids in the gram-negative cell envelope. However, E. coli harbors three distinct enzymes that synthesize CL: ClsA, ClsB, and ClsC. This redundancy suggests that CL is essential for bacterial fitness, yet CL-deficient bacteria are viable. Although multiple CL-protein interactions have been identified, the role of CL still remains unclear. To identify genes that impact fitness in the absence of CL, we analyzed high-density transposon (Tn) mutant libraries in combinatorial CL synthase mutant backgrounds. We found LpxM, which is the last enzyme in lipid A biosynthesis, the membrane anchor of lipopolysaccharide (LPS), to be critical for viability in the absence of clsA Here, we demonstrate that CL produced by ClsA enhances LPS transport. Suppressors of clsA and lpxM essentiality were identified in msbA, a gene that encodes the indispensable LPS ABC transporter. Depletion of ClsA in ∆lpxM mutants increased accumulation of LPS in the inner membrane, demonstrating that the synthetic lethal phenotype arises from improper LPS transport. Additionally, overexpression of ClsA alleviated ΔlpxM defects associated with impaired outer membrane asymmetry. Mutations that lower LPS levels, such as a YejM truncation or alteration in the fatty acid pool, were sufficient in overcoming the synthetically lethal ΔclsA ΔlpxM phenotype. Our results support a model in which CL aids in the transportation of LPS, a unique glycolipid, and adds to the growing repertoire of CL-protein interactions important for bacterial transport systems.

Entities:  

Keywords:  ClsA; LpxM; MsbA; cardiolipin; lipopolysaccharide

Year:  2021        PMID: 33833055     DOI: 10.1073/pnas.2018329118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  Acinetobacter baumannii Can Survive with an Outer Membrane Lacking Lipooligosaccharide Due to Structural Support from Elongasome Peptidoglycan Synthesis.

Authors:  Marta Nieckarz; Victor Pinedo; Brent W Simpson; Amanda B McLean; Felipe Cava; M Stephen Trent
Journal:  mBio       Date:  2021-11-30       Impact factor: 7.867

2.  Absence of YhdP, TamB, and YdbH leads to defects in glycerophospholipid transport and cell morphology in Gram-negative bacteria.

Authors:  Martin V Douglass; Amanda B McLean; M Stephen Trent
Journal:  PLoS Genet       Date:  2022-02-28       Impact factor: 5.917

3.  Energetics of lipid transport by the ABC transporter MsbA is lipid dependent.

Authors:  Dawei Guo; Himansha Singh; Atsushi Shimoyama; Charlotte Guffick; Yakun Tang; Sam M Rowe; Timothy Noel; David R Spring; Koichi Fukase; Hendrik W van Veen
Journal:  Commun Biol       Date:  2021-12-09

Review 4.  Checkpoints That Regulate Balanced Biosynthesis of Lipopolysaccharide and Its Essentiality in Escherichia coli.

Authors:  Gracjana Klein; Alicja Wieczorek; Martyna Szuster; Satish Raina
Journal:  Int J Mol Sci       Date:  2021-12-24       Impact factor: 5.923

5.  A New Factor LapD Is Required for the Regulation of LpxC Amounts and Lipopolysaccharide Trafficking.

Authors:  Alicja Wieczorek; Anna Sendobra; Akshey Maniyeri; Magdalena Sugalska; Gracjana Klein; Satish Raina
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

6.  Molecular Basis of Essentiality of Early Critical Steps in the Lipopolysaccharide Biogenesis in Escherichia coli K-12: Requirement of MsbA, Cardiolipin, LpxL, LpxM and GcvB.

Authors:  Patrycja Gorzelak; Gracjana Klein; Satish Raina
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

Review 7.  Shigella Outer Membrane Vesicles as Promising Targets for Vaccination.

Authors:  Muhammad Qasim; Marius Wrage; Björn Nüse; Jochen Mattner
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.